drugset / Trial / NCT04539626

Estrogen Therapy in Non-severe COVID-19 Patients

NCT04539626

Unknown 44 enrolled CMN "20 de Noviembre"
RandomizedParallel-groupSingle-blindTreatment

Summary

The primary objective of this study is to evaluate the effect of additional estradiol estrogen therapy on clinical response and mortality in non-severe COVID-19 patients

Timeline

Start
2020-10-01
Primary completion
2023-04-03
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject ethinyl estradiol Small molecule 0.6 mg Other
Subject ethinyl estradiol Small molecule 6 mg Other

Indications